Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M41,452Revenue (TTM) $M4,435Net Margin (%)16.4Altman Z-Score13.5
Enterprise Value $M40,965EPS (TTM) $6.3Operating Margin %29.3Piotroski F-Score7
P/E(ttm)62.7Beneish M-Score-2.4Pre-tax Margin (%)28.8Higher ROA y-yY
Price/Book11.010-y EBITDA Growth Rate %--Quick Ratio3.1Cash flow > EarningsY
Price/Sales10.25-y EBITDA Growth Rate %--Current Ratio3.4Lower Leverage y-yY
Price/Free Cash Flow57.6y-y EBITDA Growth Rate %43.6ROA % (ttm)14.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)21.3Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M105ROIC % (ttm)24.8Gross Margin Increase y-yN

Gurus Latest Trades with REGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNVanguard Health Care Fund 2016-03-31 Add0.71%$359.68 - $542.87
($414.39)
$ 394.49-5%Add 38.98%3,169,490
REGNRon Baron 2016-03-31 Reduce-0.01%$359.68 - $542.87
($414.39)
$ 394.49-5%Reduce -32.86%5,011
REGNJoel Greenblatt 2016-03-31 Reduce-0.01%$359.68 - $542.87
($414.39)
$ 394.49-5%Reduce -39.26%2,525
REGNMario Gabelli 2016-03-31 Reduce$359.68 - $542.87
($414.39)
$ 394.49-5%Reduce -2.54%1,343
REGNKen Fisher 2016-03-31 Reduce$359.68 - $542.87
($414.39)
$ 394.49-5%Reduce -0.33%613
REGNVanguard Health Care Fund 2015-12-31 Reduce-0.17%$459.82 - $587.09
($543.11)
$ 394.49-27%Reduce -6.84%2,280,494
REGNJoel Greenblatt 2015-12-31 Buy 0.02%$459.82 - $587.09
($543.11)
$ 394.49-27%New holding4,157
REGNMario Gabelli 2015-12-31 Reduce$459.82 - $587.09
($543.11)
$ 394.49-27%Reduce -35.76%1,378
REGNKen Fisher 2015-12-31 Add$459.82 - $587.09
($542.9)
$ 394.49-27%Add 22.02%615
REGNVanguard Health Care Fund 2015-09-30 Reduce-0.32%$451.82 - $592.4
($537.03)
$ 394.49-27%Reduce -11.45%2,447,894
REGNRon Baron 2015-09-30 Reduce$451.82 - $592.4
($537.03)
$ 394.49-27%Reduce -0.21%7,463
REGNKen Fisher 2015-09-30 Reduce$451.82 - $592.4
($537.03)
$ 394.49-27%Reduce -10.80%504
REGNVanguard Health Care Fund 2015-06-30 Reduce-0.15%$438.27 - $539.4
($487.44)
$ 394.49-19%Reduce -5.36%2,764,540
REGNKen Fisher 2015-06-30 Add$438.27 - $539.4
($487.44)
$ 394.49-19%Add 5.81%565
REGNMario Gabelli 2015-06-30 Reduce$438.27 - $539.4
($487.44)
$ 394.49-19%Reduce -2.05%2,145
REGNRon Baron 2015-06-30 Reduce$438.27 - $539.4
($487.44)
$ 394.49-19%Reduce -0.15%7,479
REGNKen Fisher 2015-03-31 Add$396.89 - $488.87
($423.8)
$ 394.49-7%Add 1.91%534
REGNVanguard Health Care Fund 2014-12-31 Add0.12%$328.07 - $434.95
($393.59)
$ 394.490%Add 4.49%2,921,000
REGNJoel Greenblatt 2014-12-31 Sold Out -0.01%$328.07 - $434.95
($394.04)
$ 394.490%Sold Out0
REGNJoel Greenblatt 2014-09-30 Add$296.41 - $364.41
($335.27)
$ 394.4918%Add 60.05%1,410
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Van Plew Daniel PEVP & General Mgr Industrial O 2016-05-18Sell4,413$385.772.26view
GOLDSTEIN JOSEPH LDirector 2016-04-06Sell2,000$425-7.18view
GOLDSTEIN JOSEPH LDirector 2016-03-21Sell2,000$3755.2view
Sanofi10% Owner 2016-02-17Buy161,157$392.460.52view
Sanofi10% Owner 2016-01-12Buy83,938$465.04-15.17view
McCorkle Douglas SVP Controller and Asst Treasur 2015-12-29Sell3,954$552.08-28.54view
BROWN MICHAEL SDirector 2015-12-10Sell3,000$546.45-27.81view
YANCOPOULOS GEORGEPresident Regeneron Laboratori 2015-12-02Sell43,348$549.03-28.15view
VAGELOS P ROYChairman of the Board 2015-11-18Sell17,240$587.9-32.9view
SING GEORGE LDirector 2015-11-18Sell3,500$580-31.98view

Quarterly/Annual Reports about REGN:

News about REGN:

Articles On GuruFocus.com
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Regeneron Pharmaceuticals May 23 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 
Weekly CFO Sells Highlights: Facebook, Fitbit, Regeneron Pharmaceuticals Nov 23 2015 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Weekly CFO Sells Highlight: Acadia Healthcare, Facebook, Regeneron Pharmaceuticals Aug 24 2015 
Weekly Insider Sells Highlights: FB, AET, REGN, TYC Aug 18 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 

More From Other Websites
[$$] Biotech Named as Sponsor May 25 2016
Regeneron Announces Important US Prescribing Information Clarification for EYLEA® (aflibercept)... May 25 2016
Lilly says new type of pain drug could lessen need for opioids May 24 2016
How I Made a Huge Profit on Regeneron -- And It was One of My Biggest Mistakes Ever May 24 2016
Sanofi Is Shuffling Its Exec Roster Amid Continued Struggles May 23 2016
Why Albany added 1,400 private sector jobs instead of losing 800 May 19 2016
History Says Now Is The Time To Buy This Biotech Firm May 18 2016
Regeneron Pharmaceuticals (REGN) Stock is the 'Chart of the Day' May 18 2016
After-hours buzz: Alphabet, LendingClub, Target & more May 17 2016
IBB’s Large Caps: Regeneron Pharmaceuticals Rose 6% May 17 2016
Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US :... May 17 2016
Regeneron’s Target Price Downgraded by Wall Street Analysts May 17 2016
Pfizer's Anacor deal showcases new wave of eczema therapies May 17 2016
Analysis - Pfizer's Anacor deal showcases new wave of eczema therapies May 17 2016
Regeneron Pharmaceuticals’ Collaboration Revenue in 1Q16 May 16 2016
Pfizer Acquiring Anacor For Potential Blockbuster Eczema Drug May 16 2016
Regeneron's Spike Not Tied to Pfizer-Anacor Deal, but It Doesn't Hurt May 16 2016
Drug developer negotiating deal to buy Pitney Bowes building May 16 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)